icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
 
 
  Reported by Jules Levin EASL 2011 Berlin March 31-Apr 2
 
A Corsa, M Robinson, H Yang, B Peng, G Cheng, B Schultz, O Barauskas, M Hung, X Liu, C Yang, Y Wang, G Rhodes, R Pakdaman, M Shen, C Sheng, C Kim, W Delaney Gilead Sciences Foster City, CA USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

References
 
1. E. Lawitz; J. M. Hill; T. C. Marbury; M. Rodriguez-Torres; M. P. DeMicco; J. Quesada; P. Shaw; S. C. Gordon; M. J. Shelton; D. H. Coombs; J. Zong; A. Bae; K. A. Wong; H. Mo; E. Mondou; K. R. Hirsch; W. E. Delaney. Three-Day, Dose-Ranging Study of the HCV NS3 Protease Inhibitor GS-9451. Hepatology Vol 52, S1 p714A